BIOADAPTIVES, Inc. (BDPT) intrinsic value & 10-year financials
BIOADAPTIVES, Inc. (BDPT) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 10.7% a year to $18.3K, with an average return on invested capital of 98.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.00
- Market cap
- $18.1K
- Revenue (FY2025)
- $18.3K
- Revenue growth (10-yr CAGR)
- 10.7%
- ROIC (10-yr avg)
- 98.2%
- Free cash flow (FY2025)
- -$534.0K
BDPT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $18.3K | -$1.6M | -$0.15 | -$534.0K | -5701.8% | 58.0% |
| FY2024 | $12.7K | -$899.2K | -$0.11 | -$249.5K | -4752.5% | 38.7% |
| FY2023 | $28.6K | -$712.5K | — | — | -801.4% | 46.0% |
| FY2022 | $17.2K | -$895.6K | — | — | -2456.3% | 33.2% |
| FY2021 | $19.8K | -$1.0M | — | — | — | 85.0% |
| FY2020 | $16.3K | -$847.2K | — | — | — | 76.4% |
| FY2019 | $9.9K | -$238.9K | — | — | — | 31.2% |
| FY2018 | — | -$1.4M | — | — | — | 403.5% |
| FY2017 | — | — | — | — | — | — |
| FY2015 | — | -$227.4K | — | — | — | 111.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BIOADAPTIVES, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
BIOADAPTIVES, INC. has earned high returns on invested capital, averaging 53.8% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
BIOADAPTIVES, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, BIOADAPTIVES, INC. is modeled at 8.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-3.17 per share.